Senti Biosciences Holdings, Inc. (SNTI) is a clinical-stage biotechnology company based in South San Francisco that engineers "Gene Circuits" — synthetic biology programs designed to make cell and gene therapies more precise — with its lead asset, SENTI-202, in Phase 1 development for relapsed or refractory acute myeloid leukemia. The stock traded at $0.113 on Tuesday morning, down 16.91% from Monday's close of $0.136, extending a decline that has taken the shares from roughly $0.45 in mid-August to near the $0.10 level. The immediate reason is verifiable and company-specific: Senti Bio said before the open that its board approved a one-for-thirty-three reverse stock split to cure a Nasdaq minimum bid price deficiency.
The company said the ratio was set at 1-for-33, that it takes effect at 5:00 p.m. ET on Nov. 18, and that the stock begins trading on a split-adjusted basis on Nov. 19 under the new CUSIP 816944201. Outstanding shares will fall from about 85.7 million to roughly 2.6 million.
Reverse splits are neutral on paper — value per holding is unchanged — but in practice they are sold by the market for two reasons. First, they tend to be read as confirmation of distress rather than a cure. Second, a 33-to-1 consolidation on a stock already trading in triple-digit fractions of a dollar compresses the float into a much thinner share base, which raises the sensitivity of the quote to relatively small orders. That combination explains a double-digit percentage decline on a day with no negative clinical or financial disclosure.
The split exists because Senti Bio received a Nasdaq Listing Qualifications notice on Aug. 27, 2026, after its bid price closed below $1.00 for 30 consecutive business days. The company has until Feb. 23, 2027, and needs ten consecutive closes at or above $1.00 to regain compliance.
The clock is tighter than that grace period implies. Under Nasdaq's amended rules, a stock trading at or below $0.10 for ten consecutive sessions faces an immediate delisting determination and suspension — and a hearing request does not automatically stay that suspension. With the shares now at $0.113 and having closed as low as $0.136 on Monday, the buffer to that trigger is thin, which is precisely the kind of risk that forces holders to reduce exposure rather than wait for the split.
A secondary factor is capital structure. On Nov. 9, Senti Bio signed an equity commitment letter with CPIF II-9 Limited, an affiliate of Celadon Partners SPV 24 Limited, allowing the investor to buy up to $4.55 million of common stock at Nasdaq's "Minimum Price," settled quarterly through the end of 2027. Those shares are issued at prevailing — currently very low — prices, so each drawdown adds meaningfully to the share count. That structure has weighed on the stock since mid-November and reinforces the case for de-risking ahead of a consolidation.
The move was a gap lower rather than an intraday slide: the first prints of the session came near $0.111, well below Monday's $0.136 close, and the stock then stabilized around $0.113. Turnover was light, with only about 20,000 shares changing hands in the first half hour against an average of roughly 400,000 shares a day over the past three months — a sign that a thin order book, not heavy institutional selling, drove the repricing. The shares remain far below their 50-day and 200-day moving averages and have lost more than 90% over the past 52 weeks. Broader indices opened modestly lower on rising Treasury yields, and sub-$1 micro-cap biotech names were broadly soft, but the scale of this decline is company-specific.
A score of 0 would mean no meaningful news and a move normal for the stock; 100 would mean transformative news and an extremely rare price move. This event lands at 40 out of 100. The verified news — a reverse split tied directly to a listing deficiency — is material for a company of this size, but it is a corporate action rather than a clinical, regulatory or financial surprise. The price response was about 3.5 times the stock's typical daily move of roughly 4.9%, and only twice in the last 60 sessions has an absolute move been this large. Moderate news plus a moderately unusual move produces the mid-range score.
Attention shifts to Nov. 18, when the split takes effect, and Nov. 19, when the adjusted quote begins trading. Investors will watch whether the consolidated price holds above $1.00 and whether the company can string together the ten consecutive closes needed to close out the deficiency. Third-quarter results, expected around the end of November, will be scrutinized for cash runway, operating spend and enrollment progress in the SENTI-202 program, alongside any update on the contingent value rights tied to the completed restructuring. Risks include further dilution from the equity line, the possibility of a post-split decline back below $1.00, and the unusually high volatility typical of micro-cap biotech.
Tickeron hosts hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are surfaced in the curated Trending AI Robots section. Bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, so the page offers a practical starting point for comparing approaches. Readers looking to see which automated strategies are leading right now can explore the page and evaluate the results for themselves.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The RSI Oscillator for SNTI moved out of oversold territory on November 11, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 42 similar instances when the indicator left oversold territory. In 35 of the 42 cases the stock moved higher. This puts the odds of a move higher at 83%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for SNTI just turned positive on November 11, 2026. Looking at past instances where SNTI's MACD turned positive, the stock continued to rise in 36 of 48 cases over the following month. The odds of a continued upward trend are 75%.
Following a +16.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNTI advanced for three days, in 194 of 237 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
SNTI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SNTI as a result. In 79 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNTI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for SNTI entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.465) is normal, around the industry mean (3.586). P/E Ratio (-0.095) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (166.667) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. SNTI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNTI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology